Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience

Jowita Sroka-Tomaszewska; Barbara Bulińska; Aleksandra Wilkowska; Roman Nowicki; Magdalena Trzeciak

doi:10.5114/ada.2023.133818

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2023
vol. 40

Send email

Copy url:

abstract:

Original paper

Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience

Jowita Sroka-Tomaszewska

¹

,

Barbara Bulińska

¹

,

Aleksandra Wilkowska

¹

,

Roman J. Nowicki

¹

,

Magdalena Trzeciak

¹

Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Adv Dermatol Allergol 2023; XL (6): 747-752

DOI: https://doi.org/10.5114/ada.2023.133818

Online publish date: 2024/01/08

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Sroka-Tomaszewska J, Bulińska B, Wilkowska A, Nowicki RJ, Trzeciak M. Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(6):747-752. doi:10.5114/ada.2023.133818.

APA

Sroka-Tomaszewska, J., Bulińska, B., Wilkowska, A., Nowicki, R. J.,  & Trzeciak, M. (2023). Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(6), 747-752. https://doi.org/10.5114/ada.2023.133818

Chicago

Sroka-Tomaszewska, Jowita, Barbara Bulińska, Aleksandra Wilkowska, Roman J Nowicki,  and Magdalena Trzeciak. 2023. "Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 40 (6): 747-752. doi:10.5114/ada.2023.133818.

Harvard

Sroka-Tomaszewska, J., Bulińska, B., Wilkowska, A., Nowicki, R.,  and Trzeciak, M. (2023). Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(6), pp.747-752. https://doi.org/10.5114/ada.2023.133818

MLA

Sroka-Tomaszewska, Jowita et al. "Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 40, no. 6, 2023, pp. 747-752. doi:10.5114/ada.2023.133818.

Vancouver

Sroka-Tomaszewska J, Bulińska B, Wilkowska A, Nowicki R, Trzeciak M. Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(6):747-752. doi:10.5114/ada.2023.133818.

Introduction:
Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody targeting the a subunit of the IL-4 receptor and is responsible for blocking the signalling of interleukin (IL) 4 (IL-4) and IL-13. Clinical trials conducted for over 10 years have confirmed the efficacy and safety of dupilumab’s treatment for atopic dermatitis.

Aim:
Evaluating the efficacy of dupilumab treatment in patients with moderate and severe atopic dermatitis in real life.

Material and methods:
We retrospectively evaluated medical records of patients treated with dupilumab for atopic dermatitis at the Department of Dermatology, Venereology and Allergology in Gdansk.

Results:
Ten patients in total were studied. They received dupilumab with standard dosing. The mean percentage reduction in SCORAD score was 52.16% in 8 weeks. Dupilumab was generally well tolerated and did not cause serious side effects. The most common adverse event was conjunctivitis.

Conclusions:
Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.

keywords:

Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience

Jowita Sroka-Tomaszewska 1 , Barbara Bulińska 1 , Aleksandra Wilkowska 1 , Roman J. Nowicki 1 , Magdalena Trzeciak 1

atopic dermatitis, dupilumab, biological treatment

Jowita Sroka-Tomaszewska

¹

,

Barbara Bulińska

¹

,

Aleksandra Wilkowska

¹

,

Roman J. Nowicki

¹

,

Magdalena Trzeciak

¹